Active, not recruitingPhase 2NCT03401788
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
Studying Von Hippel-Lindau disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Belzutifan(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2026
Study locations (11)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- Vanderbilt Medical Center, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Huntsman Cancer Institute, Salt Lake City, Utah, United States
- Aarhus University Hospital, Aarhus, Denmark
- Hospital Georges Pompidou, Paris, France
- Cambridge University Hospital, Cambridge, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03401788 on ClinicalTrials.govOther trials for Von Hippel-Lindau disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07171905CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau DiseaseIRCCS Ospedale San Raffaele
- ENROLLING BY INVITATIONNANCT05737602Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau DiseaseMassachusetts General Hospital
- RECRUITINGPHASE2NCT07167329Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL TrialJosé Claudio Casali da Rocha
- RECRUITINGNCT05955014Data Collection Protocol for Patients With Von Hippel Lindau DiseaseM.D. Anderson Cancer Center
- RECRUITINGNCT06194669Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule CellsIRCCS San Raffaele
- RECRUITINGNANCT05424016Propranolol and Von Hippel-Lindau DiseaseAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Merck Sharp & Dohme LLC